Optical coherence tomography changes before the development of choroidal neovascularization in second eyes of patients with bilateral wet macular degeneration

Eye

Volumn 26, Issue 3, 2012, Pages 394-399

  Amissah Arthur, K N ^a,b   Panneerselvam, S ^a   Narendran, N ^a   Yang, Y C ^a  

^a NEW CROSS HOSPITAL   (United Kingdom)

^b CITY HOSPITAL   (United Kingdom)

Author keywords

fellow eye risk; OCT appearance; OCT progression; second eye involvement; wet AMD

Indexed keywords

RANIBIZUMAB;

AGED; ARTICLE; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; PIGMENT EPITHELIUM; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; RETROSPECTIVE STUDY; SUBRETINAL FLUID;

EID: 84863269367     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2011.335     Document Type: Article

References (17)

1. Macular Photocoagulation Study Group. Five-year followup of fellow eyes of patients with age-related macular degeneration and unilateral extrafoveal choroidal neovascularization. Arch Ophthalmol 1993; 111(9): 1189-1199.
2. Connell PP, Keane PA, Oeill EC, Altaie RW, Loane E, Neelam K et al. Risk factors for age-related maculopathy. J Ophthalmol 2009; 2009: 360764.
3. Wong TY, Wong T, Chakravarthy U, Klein R, Mitchell P, Zlateva G et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology 2008; 115(1): 116-126.
4. Solomon SD, Jefferys JL, Hawkins BS, Bressler NM, Bressler SB. Risk factors for second eye progression to advanced age-related macular degeneration: SST report no. 21 Submacular Surgery Trials Research Group. Retina (Philadelphia, Pa) 2009; 29(8): 1080-1090.
5. Barbazetto IA, Saroj N, Shapiro H, Wong P, Ho AC, Freund KB. Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. Am J Ophthalmol 2010; 149(6): 939.e1-946.e1.
6. Clemons TE, Milton RC, Klein R, Seddon JM, Ferris FL. Risk factors for the incidence of advanced age-related macular degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19. Ophthalmology 2005; 112(4): 533-539. (Pubitemid 41108849)
7. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355(14): 1419-1431. (Pubitemid 44511557)
8. Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 2007; 144(6): 850-857.
9. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008; 145(2): 239-248.
10. Bressler NM, Chang TS, Suñer IJ, Fine JT, Dolan CM, Ward J et al. Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR. Ophthalmology 2010; 117(4): 747.e4-756.e4.
11. Chang TS, Bressler NM, Fine JT, Dolan CM, Ward J, Klesert TR et al. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a Randomized Clinical Trial. Arch Ophthalmol 2007; 125(11): 1460-1469. (Pubitemid 350106676)
12. Shona O, Gupta B, Vemala R, Sivaprasad S. Visual acuity outcomes in ranibizumab-treated neovascular age-related macular degeneration; stratified by baseline vision. Clin Exp Ophthalmol 2011; 39(1): 5-8.
13. Muether PS, Hermann MM, Koch K, Fauser S. Delay between medical indication to anti-VEGF treatment in age-related macular degeneration can result in a loss of visual acuity. Graefes Arch Clin Exp Ophthalmol 2011; 249(5): 633-637.
14. Cachulo L, Silva R, Fonseca P, Pires I, Carvajal-Gonzalez S, Bernardes R et al. Early markers of choroidal neovascularization in the fellow eye of patients with unilateral exudative age-related macular degeneration. Ophthalmologica 2011; 225(3): 144-149.
15. Bunce C, Xing W, Wormald R. Causes of blind and partial sight certifications in England and Wales: April 2007-March 2008. Eye (Lond) 2010; 24(11): 1692-1699.
16. Malamos P, Sacu S, Georgopoulos M, Kiss C, Pruente C, Schmidt-Erfurth U. Correlation of high-definition optical coherence tomography and fluorescein angiography imaging in neovascular macular degeneration. Invest Ophthalmol Vis Sci 2009; 50(10): 4926-4933.
17. Khurana RN, Dupas B, Bressler NM. Agreement of time-domain and spectral-domain optical coherence tomography with fluorescein leakage from choroidal neovascularization. Ophthalmology 2010; 117(7): 1376-1380.